MedTrace Logo

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

NCT00106262 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2007-04-18

No results posted yet for this study

Summary

This study is conducting an evaluation of two chemotherapy drugs, Velcade and Irinotecan, in women with advanced, recurrent, or metastatic cervical cancer, vaginal cancer, or vulvar cancer. Patients with cervical cancer may have received a platinum-containing treatment as systemic therapy without radiation, but is not required.

Conditions

Interventions

DRUG

Velcade (bortezomib)

DRUG

Irinotecan

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Women and Infants Hospital of Rhode Island

    lead OTHER

Principal Investigators

  • Don S Dizon, MD · Women & Infants' Hospital of Rhode Island

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00106262 on ClinicalTrials.gov